New Funding Dean's List

Notable & novel scientific awards to celebrate. All New Funding Awards can be viewed here

2018: July, August, September, October, November & December
2019: January, February

FEBRUARY 2019

Competitive Renewals

Kim Leslie  •  Obstetrics & Gynecology
Targeted Therapy for Endometrial Cancer
NIH R01  •  5 years

New Federal Awards

Corinne Griguer  •  Radiation Research Lab
Paracrine Signaling in Glioma: Bioenergetics Heterogeneity and Chemoresistance
NIH R21  •  1 year

Balaji Manicassamy  •  Microbiology & Immunology
Endothelial Cell Tropism in the Pathogenesis and Host Response against Influenza Viruses
NIH R01  •  4 years

Other Awards

Nicholas Mohr  •  Emergency Medicine
Evaluating the Role of Telemedicine in Improving Rural Emergency Department Sepsis Care
ABHRQ K08

Mohammed Milhem  •  Internal Medicine
AST-008-102: A Phase 1b/2 Study of AST-008 Combined with Pembrolizumab in Patients with Advanced Solid Tumors
Exicure, Inc.

Mohammed Milhem  •  Internal Medicine
A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
Format Therapeutics, Inc.

Mohammed Milhem  •  Internal Medicine
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Nektar Therapeutics

Michael O'Donnell  •  Urology
A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC)
Medical Enterprises Europe B.V.

Yehudith Assouline-Dayan  •  Internal Medicine
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis
Regeneron Pharmaceuticals, Inc.

 

JANUARY 2019

Competitive Renewals

Kelly Falls  •  Radiation Research Laboratory
Targeting lung and breast cancer cell oxidative metabolism with D-penicillamine and disulfiram
NIH F30  •  2 years

George Weiner  •  Holden Comprehensive Cancer Center
Institutional Research Grant
American Cancer Society

New Federal Awards

Ryan Boudreau  •  Internal Medicine
Regulation and role of the cardiac sodium channel Nav1.5 in heart failure
NIH R01  •  5 years

John Fingert  •  Ophthalmology & Visual Sciences
Michael Anderson  •  Molecular Physiology & Biophysics

CRISPR/CAs9 approaches to model exfoliation syndrome
NIH R21  •  2 years

Dao-Fu Dai  •  Pathology
The role of energy sensor signaling in mitochondrial cardiomyopathy
NIH K08  •  5 years

Corinne Griguer  •  Radiation Research Laboratory
Cytochrome C Oxidase: Biomarker in Newly Diagnosed Glioblastomas Multiforme
NIH U01  •  2 years

Denise Hodgson-Zingman  •  Internal Medicine
A New Pacing Approach for Cardioprotection and Repair In Heart Failure
NIH R21  •  2 years

Alejandro Pezzulo  •  Internal Medicine
Heat-shock protein 90 modulates goblet cell metaplasma in human airway epithelia
NIH K01  •  5 years

Mark Santillan  •  Obstetrics & Gynecology
Vasopressin and Preeclampsia: Early Mechanisms for Prevention
NIH R01  •  5 years

Budd Tucker  •  Ophthalmology & Visual Sciences
Robert Mullins •  Ophthalmology & Visual Sciences

Molecular Basis of Complement Defense in Choroidal Endothelial Cells
NIH R21  •  2 years

Other Awards

Michael Tansey  •  Pediatrics
Evolucumab for Low Density Lipoprotein-Cholesterol (LDL-C) Reduction, as Add-On to Diet and Lipid-Lowering Therapy, in Pediatric Subjects 10 to 17 Years of Age with Heterozygous Familial Hypercholesterolemia (HeFH)
Amgen, Inc.

Eric Taylor  •  Biochemistry
Metabolomic Mechanisms of Action in the Mitochondrial Pyruvate Carrier Modulator MSDC-0602K
Cirius Therapeutics, Inc.

Yousef Zakharia  •  Internal Medicine
Proof of concept for lenvatinib and reverolimus prior to cytoreductive nephrectomy in eligible patients with locally advanced metastatic renal cell carcinoma (RCC)
Eisai, Inc.

Yousef Zakharia  •  Internal Medicine
Combination of Axitinib and Selenium in the Chemical Composition of Selenomethione (SLM) for adult patients with advanced metastatic clear cell renal cell carcinoma (CCRCC)
Pfizer, Inc.

Rohan Garje  •  Internal Medicine
Study of 177Lu-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistance Prostate Cancer
Endocyte, Inc.

John Bernat  •  Pediatrics
Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease
Protalix Biotherapeutics

John Engelhardt  •  Anatomy & Cell Biology
Statement of Work
Talee Bio, Inc.

Andrea Swenson  •  Neurology
Arimoclomol in Amyotrophic Lateral Sclerosis
Worldwide Clinical Trials, Inc.

 

NOVEMBER & DECEMBER 2018

Competitive Renewals

John Harty  •  Microbiology & Immunology
T resident memory in the lung
NIH R01  •  5 years

Denise Martinez  •  Medicine Administration
Summer Health Professions Education Program
Robert Wood Johnson Foundation

New Federal Awards

Anil Chauhan  •  Internal Medicine
Novel Therapeutic Intervention to Treat Ischemic Stroke
NIH R01  •  5 years

James Davis  •  Pediatrics
Fungal and Host Factors in Initiation of Cryptococcal Persistence
NIH K08  •  4 years

Krystal Parker  •  Psychiatry
Cerebellar circuits, timing, and cognition
NIH R01  •  5 years

David Weiss  •  Microbiology & Immunology
REU Site: Microbiology at The University of Iowa
NSF  •  3 years

Other Awards

Matthew Howard  •  Neurosurgery
Casual mapping of emotion networks with concurrent electrical stimulation of fMRI
California Institute of Technology

C. Michael Knudson  •  Tissue Procurement Core
TPC NDI PDX
Leidos, Inc.

Richard Smith & Carla Nester  •  Otolaryngology
C3 Glomerulopathy - A Longitudinal and Disovery Study
Novartis Corporation

Doug Laux  •  Internal Medicine
A randomized, open-label, multicenter, phase 1b/2 trial evaluating the safety and efficacy of intratumorally-administered ilixadencel in combination with CPI
Immunicum AB

John Bernat  •  Pediatrics
A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 to Agalside Beta on Renal Function in patients with Fabry Disease previously treated with Agalsidase Beta
Protalix Biotherapeutics

 

OCTOBER 2018

New Federal Awards

Ted Abel  •  Physiology & Biophysics
Molecular, Cellular and Circuit Effects of Sleep Deprivation on Hippocampus Function
NIH R01  •  5 years

Donna Hammond  •  Anesthesia
Nicotinamide Riboside for Relief of Taxane-Induced Sensory Neuropathy
NIH R21  •  2 years

Alison Lynch  •  Psychiatry
Collaborative Medication Assisted Treatment in Iowa 
SAMHSA H79  •  3 years

Frida Teran  •  Neurology
A novel dietary therapy for epilepsy: potential mechanisms of action
NIH F31  •  4 years

Aliye Uc  •  Pediatrics
Non-Pharmacological Pain Intervention for Pediatric Chronic Pancreatitis
NIH R01  •  5 years

Jason Wilken  •  Physical Therapy & Rehabilitation Science
Comparative Effect of Commercially Available Custom Dynamic Orthoses
US DOD  •  4 years

Other Awards

Ferhaan Ahmad  •  Internal Medicine
EXPLORER-HCM
MyoKardia, Inc.

Carryn Anderson  •  Radiation Oncology
Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis
Galera Therapeutics, Inc.

David Elliott  •  Internal Medicine
Study in LHA-DQ2.5+ Adults with Celiac Disease to Assess the Effect of Nexvax 2 on Symptoms after Masked Gluten Food Challenge
ImmusanT, Inc.

Muhammad Furqan  •  Internal Medicine
CMP-001 in Combination with Atezolizumab with and without Radiation Therapy in Subjects with Advanced Non-Small Cell Lung Cancer
Checkmake Pharmaceuticals

Delwyn Miller  •  Psychiatry
T2 PROTECT AD
University of California, San Diego

Michael O'Donnell  •  Urology
Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder
Hoosier Cancer Research Network, Inc.

Antonio Sanchez  •  Internal Medicine
Rifaximin Soluble Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy
Salix Pharmaceuticals, Inc.

Margarida Silverman  •  Internal Medicine
Ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation
Incyte Corporation

Lucy Wibbenmeyer  •  Surgery
Efficacy and safety of NexoBrid compared to Standard of Care treatment
MediWound, Inc.

 

SEPTEMBER 2018 

New Federal Awards

Joe Cullen & Doug Spitz  •  Surgery & Rad Onc
Exploiting Redox Metabolism Using Pharmacological Ascorbate for Cancer Therapy 
NIH P01  •  5 years

Joseph Buckwalter  •  Orthopedics & Rehabilitation
Translating Metabolic Responses to Mechanical Insult into Early Interventions to Prevent PTOA
US Department of Defense

Paul McCray  •  Pediatrics
CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides  
NIH UG3  •  3 years

Hai-Hai Xue  •  Microbiology
Ezh2 regulates follicular helper T cell differentiation 
NIH R01  •  5 years

Chris Adams  •  Internal Medicine
Novel signaling pathways underlying skeletal muscle atrophy
NIH R01  •  5 years

David Weiss  •  Microbiology
Peptidoglycan binding protein specificity and bacterial cell division 
NIH R01  •  4 years

Georgina Aldridge  •  Neurology
Cortical Mechanisms in Lewy Body Dementia 
NIH K08  •  5 years

Mitchell Coleman  •  Radiation Oncology
Do Changes in Thiol Metabolism Mediate Osteoarthritis Progression? 
NIH R00  •  3 years

Peg Nopoulos  •  Psychiatry
Transfusion of Prematurity Early School Age Follow-up (TOP 5) CCC  
NIH UG3  •  1 year

Jeffrey Segar  •  Pediatrics
Fenoldopam to prevent renal dysfunction in indomethacin treated preterm infants  
NIH R21  •  2 years

Sharon Idiga  •  Pharmacology
Endocrine Circuit Regulating Sugar Satiety 
NIH F31  •  2 years

Alexander Greiner  •  Internal Medicine
MSX1 in Cardiac Fibrosis and Sudden Death  
NIH F30  •  4 years

Competitive Renewals

David Stoltz  •  Internal Mediciner
Origins of Cystic Fibrosis Airway Disease  
NIH P01  •  5 years

Rob Cornell  •  Anatomy & Cell Biology
Dissecting the transcriptional network governing differentiation of periderm
NIH R56  •  1 year

Todd Washington  •  Biochemistry
Mechanisms of Damaged DNA Replication in Eukaryotes 
NIH R01  •  4 years

Clinical Trial Support

Steven Polyak  •  Internal Medicine
Upadacitinib (ABT-494) in Subjects with Crohn's Disease
AbbVie Inc.

Randy Loftus  •  Anesthesia
Reducing Perioperative S. aureus Transmission
Anesthesia Patient Safety Foundation

Mo Milhem  •  Internal Medicine
DSP-7888 Dosing in Combination with Immune Checkpoint Inhibitors in Adult Subjects with Advanced Solid Tumors
INC Research, LLC

Steven Lentz  •  Internal Medicine
Pathfinder 8
Novo Nordisk, Inc.

Kirill Nourski  •  Neurosurgery
Mechanisms of anesthetic-induced unconsciousness
University of Wisconsin-Madison

 

AUGUST 2018 

New Federal Awards

Enrique Leira  •  Neurology
UI Regional Stroke Research Network 
NIH U21  •  5 years

Robert Weiss  •  Internal Medicine
Injury in Calcific Aortic Valve Disease
NIH R01  •  4 years

Stephen Hillis  •  Radiology
Generalized Obuchowski-Rockette Methodology for Analysis of Radiologic Diagnostic Imaging
NIH R01  •  4 years

Michael Anderson  •  Physiology
Genetic modifiers of Cep290-mediated retinal degeneration  
NIH R21  •  2 years

Rudragouda Channappanavar  •  Microbiology
Interferon lambda in host protection during aging 
NIH R21  •  2 years

Ali Jabbari  •  Dermatology
Defining T helper cell associated cytokines and mechanisms in Alopecia Areata   
NIH K08  •  3 years

Competitive Renewals

Rob Cornell  •  Anatomy & Cell Biology
Regulation of the Melanocyte Lineage by the AP2 Transcription Factor Family
NIH R01  •  5 years

Rob Piper  •  Physiology
Ubiquitin-dependent sorting in endosomes and the TGN
NIH R01  •  4 years

Clinical Trial Support

Steven Polyak  •  Internal Medicine
Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease
AbbVie, Inc

Mark Santillan  •  Obstetrics & Gynecology
Mechanisms of Early and Late Postpartum Hypertension in Human Preeclampsia
American Heart Association

Huy Tran  •  Internal Medicine
Obeticholic Acid in Subjects with Cirrhosis
Intercept Pharmaceuticals, Inc.

Michael Ohl  •  Internal Medicine
Public Health-Partnered Tele-Medical Pre-Exposure Prophylaxis Delivery in a Rural State
Iowa Department of Public Health

Sneha Deepak Phadke  •  Internal Medicine
Alpelisib plus fulvestrant or letrozole in patients with PIK3CA
Novartis

Muhammad Furqan  •  Internal Medicine
First-Line Therapy in Patients with Metastatic NSCLC
Pharmaceutical Research Associates

 

JULY 2018 

New Federal Awards

Dan Weeks  •  Biochemistry
Amyloids, aggregates and nucleolar activity in Xenopus development
NIH R01  •  4 years

Frank Faraci  •  Internal Medicine
Central RAAS and Brain Small Vessel Disease
NIH R01  •  5 years

Robert Block  •  Anesthesia
General Anesthesia During Early Childhood and Brain Development 
NIH R01  •  5 years

Wendy Maury  •  Microbiology
Modeling Filovirus Infection of and Trafficking through Skin  
NIH R01  •  4 years

Catherine Musselman  •  Biochemistry
Molecular mechanisms of histone signaling in a chromatin relevant context  
NIH R35  •  5 years

Adam Dupuy  •  Anatomy & Cell Biology
The role germline polymorphisms on ALL susceptibility  
NIH R21  •  2 years

Bradley Erickson  •  Urology
Understanding the Role of Local & Systemic Inflammation in Male Urethral Stricture Disease  
NIH R21  •  2 years

Rebecca Dodd  •  Internal Medicine
Mechanisms of NF1+/- Myeloid Cell Function in MPNSTs
US Department of Defense

Loreen Herwaldt  •  Internal Medicine
SHEPheRD RFTOP 2018 Domain-1-A001
US Dept of HHS 

Laurie Gutmann, Harold Adams, Nandakumar Narayanan, Mike Shy, Katherine Matthews & Peggy Nopoulos  •  Neurology, Pediatrics & Psychiatry
University of Iowa's NeuroNEXT Clinical Research Site   
NIH U24  •  5 years

Competitive Renewals

John Harty  •  Microbiology
Understanding immune regulation in blood-stage malaria
NIH R01  •  4 years

Clinical Trial Support

Mony Fraer  •  Internal Medicine
OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy
Omeros Corporation

Mo Milhem  •  Internal Medicine
UV1 Vaccine in First-Line Malignant Melanoma Patients
Ultimovacs AS